LINZESS (linaclotide)
Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC)
ApprovedMarketed
Key Facts
Indication
Irritable Bowel Syndrome with Constipation (IBS-C) and Chronic Idiopathic Constipation (CIC)
Phase
Approved
Status
Marketed
Company
About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals is a commercial-stage biotech with a singular focus on gastrointestinal health, leveraging deep GI expertise to redefine the standard of care. Its flagship product, LINZESS, is a blockbuster GC-C agonist for IBS-C and CIC, establishing the company's commercial foundation. The company's strategic direction involves expanding its pipeline through targeted acquisitions, like VectivBio for apraglutide, to address severe GI conditions with high unmet need, such as Short Bowel Syndrome with intestinal failure (SBS-IF).
View full company profile